ReviewCurrent opinion in pulmonary medicine2013
Nonsteroidal therapy of sarcoidosis.
Review in Current opinion in pulmonary medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis.BioMed research international · 2015Trial
- Rituximab in the treatment of refractory pulmonary sarcoidosis.The European respiratory journal · 2014Trial
- Latent microbial reactivation and immune dysregulation in sarcoidosis: bridging pathogenesis and precision therapeutics.Frontiers in medicine · 2025Review
- The clinical management of hepatic sarcoidosis: A systematic review.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Pulmonary granulomatosis of genetic origin.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art.Journal of clinical medicine · 2020Review
- Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments.Journal of clinical medicine · 2020Review
- White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients.Scientific reports · 2018Article
- Increased Risk of Multimorbidity in Patients With Sarcoidosis: A Population-Based Cohort Study 1976 to 2013.Mayo Clinic proceedings · 2017Article
- [Musculoskeletal manifestations of sarcoidosis].Zeitschrift fur Rheumatologie · 2017Review
- Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction.Echocardiography (Mount Kisco, N.Y.) · 2016Article
- Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.JAAD case reports · 2016Article
- Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis.Journal of translational medicine · 2016Review
- Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.Clinical pulmonary medicine · 2016Article
- Management of extrapulmonary sarcoidosis: challenges and solutions.Therapeutics and clinical risk management · 2016Review
- [Interstitial nephritis in rheumatic diseases].Zeitschrift fur Rheumatologie · 2015Review
- Sarcoidosis in the national veteran population: association of ocular inflammation and mortality.Ophthalmology · 2015Article
- Adalimumab-induced lupus serositis.BMJ case reports · 2015Article
- Overview of neurosarcoidosis: recent advances.Journal of neurology · 2015Review
- Promising new treatment targets in patients with fibrosing lung disorders.World journal of clinical cases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewNone of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT
findingsSeveral recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.